LAUSR

The introduction of FOLFIRINOX and nab-paclitaxel radically changed the natural history of pancreatic ductal adenocarcinoma (PDAC). Soon after demonstrating the positive effect in improving survival in metastatic disease, several pieces of evidence about their use in the neoadjuvant setting for locally advanced and borderlineresectable PDAC have been collected. In addition to the ability to reduce local disease burden, neoadjuvant therapy (NAT) has also been associated with improved surgical outcome. Patients undergoing pancreaticoduodenectomy (PD) after FOLFIRINOX, in particular, show an incredibly low rate of pancreatic fistula due to the fibrotic changes of the pancreatic stump found at surgery. All these promising results are pushing towards increasingly widespread use of NAT, even in case of resectable PDAC.